辅助唑来膦酸减少乳腺癌患者骨折:AZURE研究
AZURE试验评估辅助唑来膦酸对早期乳腺癌骨折的影响,中位随访84.2个月,ZOL组5年骨折率从5.9%降至3.8%,首次骨折时间显著延长(HR 0.69),但大部分获益发生在疾病复发后。
要点
- 辅助唑来膦酸降低临床骨折风险,5年骨折率从5.9%降至3.8%。
- 首次骨折时间显著延长(HR 0.69, 95%CI 0.53-0.90; P=0.0053)。
- 骨折预防获益主要在疾病复发后(HR 0.3, 95%CI 0.17-0.53; P<0.001)。
核心结论
- 辅助唑来膦酸降低早期乳腺癌患者临床骨折风险,但大部分保护作用发生在疾病复发后。
研究设计与样本
- AZURE试验(ISRCTN79831382)为学术性、多中心、随机III期研究,评估在标准治疗基础上加用唑来膦酸4 mg治疗5年对II/III期早期乳腺癌患者骨折的影响。
- 骨折数据来自骨骼相关不良事件报告,中位随访84.2个月,共966例无病生存事件。
主要发现
- 291次骨折中,207次发生在无复发时(对照组111次,唑来膦酸组96次),80次发生在复发后(对照组59次,唑来膦酸组21次)。
- 唑来膦酸组5年骨折率为3.8%(95%CI 2.9, 4.7%),对照组为5.9%(95%CI 4.8, 7.1%)。
- 唑来膦酸显著延长首次骨折时间(HR 0.69, 95%CI 0.53-0.90; P=0.0053),但骨折预防获益主要在无病生存事件后(HR 0.3; 95%CI 0.17, 0.53; P<0.001)。
- 唑来膦酸的骨折获益在各绝经亚组中相似。
临床怎么用
- 对于II/III期早期乳腺癌患者,可考虑辅助唑来膦酸以降低骨折风险,尤其关注疾病复发后的骨折预防。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The fracture impact of adjuvant bisphosphonates in breast cancer is not defined with most trials reporting changes in bone mineral density as a surrogate. The AZURE trial (ISRCTN79831382) evaluated the impact of adjuvant zoledronic acid (ZOL) on fractures. The AZURE trial is an academic, multi-centre, randomised phase III study evaluating the addition of ZOL 4 mg to standard therapy (neo/adjuvant chemotherapy and/or endocrine therapy) for 5 years (administered by intravenous (iv) infusion every 3-4 weeks for 6 doses, then 3 monthly × 8 and 6 monthly × 5) in patients with stage II/III early breast cancer. Fracture data collected as part of skeletal-related adverse event reporting were analysed after a median of 84.2 months of follow-up and 966 disease-free survival (DFS) events. We assessed number of fractures, time-to-first fracture and the incidence of fractures before and after disease recurrence. Two hundred forty-four patients reported ≥1 fracture, 140 (8.3%) in the control arm (171 fractures) and 104 (6.2%) in the ZOL arm (120 fractures). Of the 291 fractures reported, 207 fractures occurred in the absence of recurrence (control 111, ZOL 96), 80 after recurrence (control 59, ZOL 21). The 5-year fracture rate was reduced from 5.9% (95%CI 4.8, 7.1%; control) to 3.8% (95%CI 2.9, 4.7%) with ZOL. ZOL significantly increased time-to-first fracture (HR 0.69, 95%CI 0.53-0.90; P = 0.0053) but the majority of fracture prevention benefit occurred after a DFS event (HR 0.3; 95%CI 0.17, 0.53; P < 0.001). Fracture benefits from ZOL were similar across menopausal sub-groups. In conclusion, adjuvant ZOL reduced the risk of clinical fractures, the majority of this protection occurred after disease recurrence.
引用
- Wilson C, Bell R, Hinsley S, et al. Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01/04) study. Eur J Cancer. 2018. PMID: 29544162. doi:10.1016/j.ejca.2018.02.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。